Kings Point Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $729K | Sell |
14,089
-63
| -0.4% | -$3.27K | 0.06% | 117 |
|
|
2021
Q4 | $836K | Buy |
14,152
+217
| +2% | +$10.8K | 0.07% | 116 |
|
|
2021
Q3 | $599K | Buy |
13,935
+105
| +0.8% | +$4.65K | 0.05% | 129 |
|
|
2021
Q2 | $542K | Buy |
13,830
+1,313
| +10% | +$51.1K | 0.05% | 136 |
|
|
2021
Q1 | $453K | Sell |
12,517
-243,392
| -95% | -$8.64M | 0.04% | 139 |
|
|
2020
Q4 | $9.42M | Sell |
255,909
-4,337
| -2% | -$159K | 1% | 38 |
|
|
2020
Q3 | $9.06M | Buy |
260,246
+8,777
| +3% | +$308K | 1.13% | 32 |
|
|
2020
Q2 | $7.8M | Buy |
251,469
+775
| +0.3% | +$26.3K | 1.13% | 35 |
|
|
2020
Q1 | $7.76M | Buy |
250,694
+26,127
| +12% | +$890K | 1.37% | 26 |
|
|
2019
Q4 | $8.35M | Buy |
224,567
+13,228
| +6% | +$471K | 1.23% | 28 |
|
|
2019
Q3 | $7.2M | Buy |
211,339
+7,827
| +4% | +$285K | 1.22% | 32 |
|
|
2019
Q2 | $8.36M | Buy |
203,512
+4,368
| +2% | +$173K | 1.53% | 20 |
|
|
2019
Q1 | $8.02M | Sell |
199,144
-3,327
| -2% | -$133K | 1.59% | 21 |
|
|
2018
Q4 | $8.38M | Sell |
202,471
-5,120
| -2% | -$213K | 1.87% | 16 |
|
|
2018
Q3 | $8.68M | Sell |
207,591
-107
| -0.1% | -$4.12K | 1.62% | 17 |
|
|
2018
Q2 | $7.15M | Sell |
207,698
-2,825
| -1% | -$96.5K | 1.41% | 22 |
|
|
2018
Q1 | $7.09M | Buy |
210,523
+7,029
| +3% | +$242K | 1.43% | 23 |
|
|
2017
Q4 | $6.99M | Buy |
203,494
+4,655
| +2% | +$159K | 1.47% | 20 |
|
|
2017
Q3 | $6.74M | Buy |
198,839
+3,395
| +2% | +$109K | 1.5% | 23 |
|
|
2017
Q2 | $6.23M | Sell |
195,444
-10,288
| -5% | -$324K | 1.45% | 23 |
|
|
2017
Q1 | $6.68M | Sell |
205,732
-9,919
| -5% | -$313K | 1.57% | 26 |
|
|
2016
Q4 | $6.64M | Buy |
215,651
+18,709
| +9% | +$571K | 1.64% | 25 |
|
|
2016
Q3 | $6.33M | Buy |
196,942
+3,434
| +2% | +$115K | 1.67% | 22 |
|
|
2016
Q2 | $6.46M | Buy |
193,508
+3,537
| +2% | +$113K | 1.65% | 23 |
|
|
2016
Q1 | $5.34M | Buy |
189,971
+11,122
| +6% | +$318K | 1.36% | 29 |
|
|
2015
Q4 | $5.48M | Buy |
178,849
+12,442
| +7% | +$391K | 1.36% | 30 |
|
|
2015
Q3 | $4.96M | Buy |
166,407
+8,403
| +5% | +$269K | 1.3% | 32 |
|
|
2015
Q2 | $5.03M | Buy |
158,004
+2,381
| +2% | +$77.6K | 1.22% | 34 |
|
|
2015
Q1 | $5.14M | Buy |
155,623
+21,088
| +16% | +$670K | 1.29% | 33 |
|
|
2014
Q4 | $3.98M | Buy |
134,535
+2,762
| +2% | +$79.2K | 1.07% | 39 |
|
|
2014
Q3 | $3.7M | Buy |
131,773
+658
| +0.5% | +$18.5K | 1.12% | 35 |
|
|
2014
Q2 | $3.69M | Buy |
131,115
+18,335
| +16% | +$523K | 1.11% | 37 |
|
|
2014
Q1 | $3.44M | Buy |
112,780
+32,183
| +40% | +$960K | 1.12% | 35 |
|
|
2013
Q4 | $2.34M | Sell |
80,597
-34,261
| -30% | -$997K | 0.82% | 42 |
|
|
2013
Q3 | $3.13M | Buy |
114,858
+66,493
| +137% | +$1.81M | 1.2% | 37 |
|
|
2013
Q2 | $1.28M | Buy |
+48,365
| New | +$1.34M | 0.52% | 47 |
|
Other funds holding PFE
Kings Point Capital Management's PFE Position: Q1 2022 in Review
Kings Point Capital Management reduced its Pfizer (PFE) stake by 0.45% in Q1 2022, selling an estimated $3.27K and leaving 14,089 shares worth $729K. The position accounts for 0.06% of the portfolio, ranked #117.
Kings Point Capital Management first reported a position in PFE in Q2 2013 and has held it in 36 quarters since. The position peaked at $9.42M in Q4 2020. 3,195 funds tracked by Wall St. Rank hold PFE as of Q1 2022.
- Kings Point Capital Management held 14,089 shares of Pfizer worth $729K as of Q1 2022.
- Kings Point Capital Management sold 63 Pfizer shares in Q1 2022, an estimated $3.27K.
- Pfizer made up 0.06% of Kings Point Capital Management's portfolio in Q1 2022, its #117 holding.
- Kings Point Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 36 quarters since.
- Kings Point Capital Management's Pfizer position peaked at $9.42M in Q4 2020.
- 3,195 funds tracked by Wall St. Rank held Pfizer as of Q1 2022.
Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.